ArticleInvestigational new drugs2015

Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.

C S Higano et al.PubMed ↗Publisher ↗

No numbers read from the abstract.